JP2019524706A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524706A5
JP2019524706A5 JP2019500407A JP2019500407A JP2019524706A5 JP 2019524706 A5 JP2019524706 A5 JP 2019524706A5 JP 2019500407 A JP2019500407 A JP 2019500407A JP 2019500407 A JP2019500407 A JP 2019500407A JP 2019524706 A5 JP2019524706 A5 JP 2019524706A5
Authority
JP
Japan
Prior art keywords
muc16
time point
antagonist
cancer
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019500407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/041119 external-priority patent/WO2018009811A1/en
Publication of JP2019524706A publication Critical patent/JP2019524706A/ja
Publication of JP2019524706A5 publication Critical patent/JP2019524706A5/ja
Priority to JP2022026386A priority Critical patent/JP2022081519A/ja
Pending legal-status Critical Current

Links

JP2019500407A 2016-07-08 2017-07-07 Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用 Pending JP2019524706A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022026386A JP2022081519A (ja) 2016-07-08 2022-02-24 Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662360027P 2016-07-08 2016-07-08
US62/360,027 2016-07-08
PCT/US2017/041119 WO2018009811A1 (en) 2016-07-08 2017-07-07 Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022026386A Division JP2022081519A (ja) 2016-07-08 2022-02-24 Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用

Publications (2)

Publication Number Publication Date
JP2019524706A JP2019524706A (ja) 2019-09-05
JP2019524706A5 true JP2019524706A5 (cg-RX-API-DMAC7.html) 2020-08-20

Family

ID=59399484

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019500407A Pending JP2019524706A (ja) 2016-07-08 2017-07-07 Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
JP2022026386A Withdrawn JP2022081519A (ja) 2016-07-08 2022-02-24 Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022026386A Withdrawn JP2022081519A (ja) 2016-07-08 2022-02-24 Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用

Country Status (6)

Country Link
US (2) US11440969B2 (cg-RX-API-DMAC7.html)
EP (1) EP3482205A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019524706A (cg-RX-API-DMAC7.html)
CN (1) CN109690315A (cg-RX-API-DMAC7.html)
TW (2) TWI823836B (cg-RX-API-DMAC7.html)
WO (1) WO2018009811A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004630A1 (en) 2015-12-09 2017-06-15 Medizinische Universitat Wien Monomaleimide-functionalized platinum compounds for cancer therapy
TWI823836B (zh) * 2016-07-08 2023-12-01 美商建南德克公司 人類副睪蛋白４（ｈｅ４）用於評定癌症治療反應性之用途
MX2019010028A (es) 2017-02-28 2019-10-14 Seattle Genetics Inc Anticuerpos con cisteina mutada por conjugacion.
EP3802615A4 (en) * 2018-06-04 2022-04-13 Precigen, Inc. Muc16 specific chimeric antigen receptors and uses thereof
WO2022140116A1 (en) 2020-12-21 2022-06-30 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
CN113045663B (zh) * 2021-04-18 2022-04-01 深圳市国创纳米抗体技术有限公司 一种抗he4的纳米抗体1a8及其应用
CN113480658B (zh) * 2021-07-29 2022-11-04 深圳市国创纳米抗体技术有限公司 一种抗he4的纳米抗体1d9及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
SI1325932T1 (cg-RX-API-DMAC7.html) 1997-04-07 2005-08-31 Genentech Inc
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
MXPA03009510A (es) 2001-04-17 2005-04-29 Univ Arkansas Secuencias de repeticion del gen ca125 y su uso para intervenciones de diagnosticos y terapeuticas.
WO2002092836A2 (en) 2001-05-11 2002-11-21 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
US7202346B2 (en) 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
AU2003294355A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
EP1859273B1 (en) * 2005-02-16 2008-09-17 Dana-Farber Cancer Institute Methods of detecting ovarian cancer
PL2135881T3 (pl) 2005-06-20 2012-02-29 Genentech Inc Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
ES2748397T3 (es) * 2006-01-04 2020-03-16 Fujirebio Diagnostics Inc Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres de ovario
US20070212721A1 (en) * 2006-01-27 2007-09-13 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
US8623828B2 (en) 2008-12-05 2014-01-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Blocking mesothelin peptide fragments
CN119552249A (zh) 2010-06-08 2025-03-04 基因泰克公司 半胱氨酸改造的抗体和偶联物
US9980982B2 (en) * 2011-06-06 2018-05-29 Women & Infants Hospital Of Rhode Island HE4 based therapy for malignant disease
SG190466A1 (en) 2011-11-18 2013-06-28 Agency Science Tech & Res Methods for diagnosis and/or prognosis of ovarian cancer
US9127081B2 (en) 2012-05-10 2015-09-08 Washington University Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9663562B2 (en) * 2013-03-13 2017-05-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
CN103954761B (zh) * 2014-04-22 2016-05-25 广州恒泰生物科技有限公司 用于卵巢癌早中期快速诊断试剂盒及其检测方法
JP6892132B2 (ja) * 2015-11-17 2021-06-18 ザ バーリントン エイチシー リサーチ グループ インコーポレイテッド アミノチオール及びその類似体の改善された保護及び送達のための方法
TWI823836B (zh) * 2016-07-08 2023-12-01 美商建南德克公司 人類副睪蛋白４（ｈｅ４）用於評定癌症治療反應性之用途

Similar Documents

Publication Publication Date Title
JP2019524706A5 (cg-RX-API-DMAC7.html)
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2017537090A5 (cg-RX-API-DMAC7.html)
JP2011501656A5 (cg-RX-API-DMAC7.html)
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
US20210069147A1 (en) Pharmaceutical combination and uses thereof
JP2020508317A5 (cg-RX-API-DMAC7.html)
AU2020307471A1 (en) Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
RU2017121096A (ru) Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1
JP2016520082A5 (cg-RX-API-DMAC7.html)
TW201922793A (zh) Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途
KR20120083359A (ko) ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법
JP2020519675A5 (cg-RX-API-DMAC7.html)
JP2014500862A5 (cg-RX-API-DMAC7.html)
CN110114087A (zh) β-连环蛋白作为生物标记物用于使用抗DKK-1抗体治疗癌症的用途
JP2019508433A5 (cg-RX-API-DMAC7.html)
US12171763B2 (en) Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding antagonist for treating lung cancer
JP2020522555A5 (cg-RX-API-DMAC7.html)
DK2984108T3 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
TW201716434A (zh) 針對細胞內抗原之單域抗體
JP2021506817A5 (cg-RX-API-DMAC7.html)
JP2023138982A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法
CN111655725A (zh) 用于治疗癌症的组合产品
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途